Emerging natural product development strategies drive the therapeutic potential exploration and clinical translation of hydroxysafflor yellow A
- 1Department of Integrated Chinese Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China; National Clinical Research Center for Geriatric Disease, Xiangya Hospital, Central South University, Changsha, 410008, China; NATCM Key Laboratory of TCM Gan, Xiangya Hospital, Central South University, Changsha, 410008, China
- 2Department of Neurology, Xiangya Jiangxi Hospital, Central South University, Nanchang, 410008, China
- 3The College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, 410208, China
Abstract
Hydroxysafflor yellow A (HSYA) is a structurally unique quinochalcone di-C-glycoside derived from safflower that exhibits broad-spectrum therapeutic activities, including cardiovascular protective, neuroprotective effects, anti-inflammatory, and antioxidant. As the principal active component in approved clinical injections, HSYA has demonstrated notable efficacy in acute ischemic stroke (IS). Recent breakthroughs in elucidating its biosynthetic pathway have enabled semi-synthetic and de novo production, laying the groundwork for industrial-scale application. However, HSYA's clinical translation remains hindered by physicochemical instability, poor oral bioavailability, short half-life, and fragmented mechanistic understanding. Additionally, inconsistent dosing regimens and the lack of in-depth mechanism exploration limit its therapeutic optimization. This review summarizes current advances in HSYA research, including its pharmacology, formulation strategies, and translational barriers. We propose integrative solutions involving nanostructure engineering, systems pharmacology, and artificial intelligence (AI)-assisted target identification to overcome current limitations. Together, these strategies aim to establish HSYA as a generalizable paradigm for advancing natural product-based therapeutics from bench to bedside.
Related
- Treatment Effects of Different Therapeutic Strategies and Development of a Prognostic Prediction Model for Early Gastric Cancer: A Population-Based and Multicenter Study
- BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers
- Bibliometric analysis and visualization of antidepressant-gut microbiota research : From preclinical exploration to clinical translation (2000–2026)
- Congenital pulmonary airway malformation: molecular mechanisms and exploration of candidate therapeutic pathways
- Circulating Biomarkers with Artificial Intelligence for Clinical Risk Assessment and Therapeutic Monitoring: Evidence, Limitations, and Translation
BibTeX
@article{zhu2026emerging,
title = {{Emerging natural product development strategies drive the therapeutic potential exploration and clinical translation of hydroxysafflor yellow A}},
author = {Haonan Zhu and Xiao Ni and Zhe Yu and Si Liang and Yi Qiu and Jun Huang and Tao Tang and Yang Wang and En Hu and Teng Li},
journal = {Journal of Pharmaceutical Analysis},
year = {2026},
month = sep,
doi = {10.1016/j.jpha.2025.101534},
url = {https://doi.org/10.1016/j.jpha.2025.101534},
note = {CC BY},
}
RIS
TY - JOUR
TI - Emerging natural product development strategies drive the therapeutic potential exploration and clinical translation of hydroxysafflor yellow A
AU - Haonan Zhu
AU - Xiao Ni
AU - Zhe Yu
AU - Si Liang
AU - Yi Qiu
AU - Jun Huang
AU - Tao Tang
AU - Yang Wang
AU - En Hu
AU - Teng Li
PY - 2026
DA - 2026/09/01
JO - Journal of Pharmaceutical Analysis
DO - 10.1016/j.jpha.2025.101534
UR - https://doi.org/10.1016/j.jpha.2025.101534
AB - Hydroxysafflor yellow A (HSYA) is a structurally unique quinochalcone di-C-glycoside derived from safflower that exhibits broad-spectrum therapeutic activities, including cardiovascular protective, neuroprotective effects, anti-inflammatory, and antioxidant. As the principal active component in approved clinical injections, HSYA has demonstrated notable efficacy in acute ischemic stroke (IS). Recent breakthroughs in elucidating its biosynthetic pathway have enabled semi-synthetic and de novo production, laying the groundwork for industrial-scale application. However, HSYA's clinical translation remains hindered by physicochemical instability, poor oral bioavailability, short half-life, and fragmented mechanistic understanding. Additionally, inconsistent dosing regimens and the lack of in-depth mechanism exploration limit its therapeutic optimization. This review summarizes current advances in HSYA research, including its pharmacology, formulation strategies, and translational barriers. We propose integrative solutions involving nanostructure engineering, systems pharmacology, and artificial intelligence (AI)-assisted target identification to overcome current limitations. Together, these strategies aim to establish HSYA as a generalizable paradigm for advancing natural product-based therapeutics from bench to bedside.
SN - 2095-1779
SN - 2214-0883
ER -